Skip to Content
Merck
CN
  • Inhibition of amyloid fibrillation of lysozyme by phenolic compounds involves quinoprotein formation.

Inhibition of amyloid fibrillation of lysozyme by phenolic compounds involves quinoprotein formation.

FEBS letters (2012-10-13)
Shuang Feng, Xiu-Huan Song, Cheng-Ming Zeng
ABSTRACT

Numerous phenolic compounds have been reported to have an inhibitory role on amyloid formation of proteins. The present study, utilizing lysozyme as a model system, examined the anti-amyloidogenic effects of phenol and three diphenol epimers. The results indicated that catechol and hydroquinone dose-dependently inhibited lysozyme fibrillation and covalently bound to the peptide chains to form quinoproteins, showing a similar effect to benzoquinone. In contrast, phenol and resorcinol did not modify the peptide with a quinone moiety, showing no effect on lysozyme fibrillation. We suggest that quinone intermediates are the active form for a phenolic compound to inhibit lysozyme fibrillation. The modification of lysozyme with quinone moieties alters the interacting forces between peptide chains and consequently interrupts the process of lysozyme fibrillation.

MATERIALS
Product Number
Brand
Product Description

Supelco
1,4-Benzoquinone, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Resorcinol, ≥98%, FG
Sigma-Aldrich
p-Benzoquinone, reagent grade, ≥98%
Sigma-Aldrich
Resorcinol, ReagentPlus®, 99%
Supelco
p-Benzoquinone, for spectrophotometric det. of amines, ≥99.5% (HPLC)
Sigma-Aldrich
Resorcinol, BioXtra, ≥99%
Sigma-Aldrich
Resorcinol, ACS reagent, ≥99.0%
Supelco
Resorcinol, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Resorcinol, meets analytical specification of Ph. Eur., BP, 98.5-100.5% (calc. to the dried substance)